Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Low Pre-Transplant Vitamin D Levels Predict an Inferior Survival in Patients with Multiple Myeloma Undergoing an Autologous Stem Cell Transplant

Vaidya Rakhee, Shane Ahlers, Cesar Rodriguez, MD, Zanetta S. Lamar, MD, David D Hurd, MD

Blood (2016) 128 (22): 5655.

https://doi.org/10.1182/blood.V128.22.5655.5655

Published: 2016

Journal Articles

Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance) 50403

Lawrence D. Kaplan, MD, Sin-Ho Jung, PhD, Wendy Stock, MD, Nancy L. Bartlett, MD, Brandelyn Pitcher, MS, John C. Byrd, MD, Kristie A. Blum, MD, Ann S. LaCasce, MD, Noreen Fulton, Eric D. Hsi, MD, David D Hurd, MD, Myron Czuczman, John P. Leonard, MD, Bruce D. Cheson, MD

Blood (2015) 126 (23): 337.

https://doi.org/10.1182/blood.V126.23.337.337

Published: 2015

Journal Articles

The Mitochondrial Metabolism Inhibitor Cpi-613 in Combination with High Dose Ara-C (HDAC) and Mitoxantrone Is Highly Active in Poor Risk Relapsed or Refractory Acute Myeloid Leukemia (AML)

Timothy Pardee, MD PhD, Kristin Pladna, MS, Scott Isom, MS, Leslie Renee Ellis, MD, Dmitriy Berenzon, MD, Dianna Howard, MD, Megan Manuel, MSN, Sarah Dralle, MSN, David D Hurd, MD, Susan Lyerly, PA-C, Bayard L Powell, MD

Blood (2015) 126 (23): 2556.

https://doi.org/10.1182/blood.V126.23.2556.2556

Published: 2015

Journal Articles

The Mitochondrial Metabolism Inhibitor Cpi-613 Is Highly Active in Combination with High Dose Ara-C (HiDAC) and Mitoxantrone in a Phase I Study for Relapsed or Refractory Acute Myeloid Leukemia (AML)

Timothy S Pardee, MD PhD, Kristin Stadelman, MS, Scott Isom, MS, Leslie Renee Ellis, MD, Dmitriy Berenzon, MD, David D Hurd, MD, Robin Harrelson, BSN, Megan Manuel, MSN, Sarah Dralle, MSN, Susan Lyerly, PA, Bayard L. Powell, MD

Blood (2014) 124 (21): 3744.

https://doi.org/10.1182/blood.V124.21.3744.3744

Published: 2014

Journal Articles

A Phase I Study Of The Safety, Efficacy and Pharmacokinetics Of The First In Class Pyruvate Dehydrogenase Complex Inhibitor Cpi-613 In Patients With Advanced Hematologic Malignancies

Timothy Pardee, MD, PhD, King Lee, PhD, RAC, John Luddy, MS, Claudia Maturo, MS, Robert Rodriguez, BSc, MBA, Denise A Levitan, MD, David D Hurd, MD, Leslie Renee Ellis, MD, Scott Isom, MS, Robin Harrelson, BSN, Megan Manuel, MSN, Sarah Dralle, MSN, Susan Lyerly, PA, Bayard L. Powell, MD

Blood (2013) 122 (21): 486.

https://doi.org/10.1182/blood.V122.21.486.486

Published: 2013

Journal Articles

A Phase 2 Multicenter Study of Continuous Dose Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma

Todd A. Fehniger, MD/PhD, Sarah Larson, Kathryn Trinkaus, PhD, Marilyn J. Siegel, MD, David D. Hurd, MD, Kristie A. Blum, MD, Andre Goy, MD, Timothy S. Fenske, MD, Amanda Cashen, MD, Nina D. Wagner-Johnston, MD, Kenneth R. Carson, MD, Nancy L. Bartlett, MD

Blood (2012) 120 (21): 1623.

https://doi.org/10.1182/blood.V120.21.1623.1623

Published: 2012

Journal Articles

Phase III Intergroup Study of Lenalidomide (CC-5013) Versus Placebo Maintenance Therapy Following Single Autologous Stem Cell Transplant for Multiple Myeloma (CALGB 100104): Initial Report of Patient Accrual and Adverse Events.

Philip L. McCarthy, MD, Kouros Owzar, PhD, Edward A. Stadtmauer, MD, Sergio Giralt, MD, David D Hurd, MD, Hani Hassoun, MD, Craig Hofmeister, MD, Paul Richardson, M.D., Ph.D., Daniel J. Weisdorf, Marcelo C. Pasquini, MD, Vera Hars, PhD, Michael Kelly, B.S., John Postiglione, Susan Sutherland, Kenneth C. Anderson, MD, Charles Linker, MD

Blood (2009) 114 (22): 3416.

https://doi.org/10.1182/blood.V114.22.3416.3416

Published: 2009

Journal Articles

A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma.

Todd A Fehniger, MD, PhD, Sarah Larson, Kathryn Trinkaus, PhD, Marilyn J Siegel, MD, Amanda F Cashen, MD, Kristie A Blum, MD, Timothy S. Fenske, MD, David D Hurd, MD, Andre Goy, MD, John F. DiPersio, MD, PhD, Nancy L Bartlett, MD

Blood (2009) 114 (22): 3693.

https://doi.org/10.1182/blood.V114.22.3693.3693

Published: 2009

Journal Articles

Vorinostat in Combination with Pegylated Liposomal Doxorubicin and Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase I Study.

Peter M. Voorhees, MD, Cristina Gasparetto, MD, Kristy L. Richards, PhD, MD, Reynaldo Garcia, RN, OCN, John S. Strader, Madlyn Ferraro, RN, OCN, CCRC, Jennifer MacLean, RN, Diane Winans, Dominic T. Moore, PhD, Andrew Dodd, Matthew C. Foster, MD, Don A. Gabriel, MD, PhD, Thomas C. Shea, Jonathan Serody, MD, Hendrik W. van Deventer, MD, Syed Rizvi, Robert Z. Orlowski, M.D., Ph.D., David D. Hurd, MD

Blood (2009) 114 (22): 306.

https://doi.org/10.1182/blood.V114.22.306.306

Published: 2009

Journal Articles

A Phase II Multicenter Study of Lenalidomide in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL): Preliminary Results

Todd A Fehniger, MD, PhD, Sarah Larson, BA, Kathryn Trinkaus, PhD, Marilyn J Siegel, MD, John F DiPersio, MD, PhD, Amanda F Cashen, MD, David D Hurd, MD, Kristie A Blum, MD, Nancy L Bartlett, MD

Blood (2008) 112 (11): 2595.

https://doi.org/10.1182/blood.V112.11.2595.2595

Published: 2008

Journal Articles

A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) in Patients with Myelodysplastic Syndrome (MDS): Cancer and Leukemia Group B Study 10105.

Pankaj Gupta, MD, Ben L. Sanford, MS, Daohai Yu, PhD, Ravi Vij, MD, David D. Hurd, MD, Olatoyosi Odenike, MD, Clara D. Bloomfield, MD, Robert P. Hasserjian, MD, Richard A. Larson, MD

Blood (2006) 108 (11): 2665.

https://doi.org/10.1182/blood.V108.11.2665.2665

Published: 2006

Journal Articles

A Phase I Open Label Dose Escalation Study To Evaluate MEDI-507 in Patients with CD2-Positive T-Cell Lymphoma/Leukemia.

Deborah A. Casale, MS, Nancy L. Bartlett, MD, David D. Hurd, MD, Francine Foss, MD, Barbara Pro, MD, Lubomir Sokol, MD, PhD, Ronald Lieberman, MD, Hammershaimb Luz, MD

Blood (2006) 108 (11): 2727.

https://doi.org/10.1182/blood.V108.11.2727.2727

Published: 2006

Journal Articles

Feasibility of Administering Oblimersen (G3139; Genasense) with Imatinib Mesylate in Patients with Imatinib Resistant Chronic Myeloid Leukemia (CML) - Cancer and Leukemia Group B Study 10107.

Meir Wetzler, MD, Daohai Yu, PhD, Olatoyosi Odenike, MD, Eric J. Feldman, MD, David D. Hurd, MD, Eva Hoke, Vera Hars, Richard A. Larson, MD

Blood (2005) 106 (11): 1097.

https://doi.org/10.1182/blood.V106.11.1097.1097

Published: 2005

Journal Articles

Pharmacokinetics (PK) of 2 Dosing Regimens of Palifermin in Patients (Pts) with Hematologic Malignancies (HM) Undergoing High-Dose Chemoradiotherapy and Hematopoietic Stem Cell Transplantation (HSCT).

Parnian Zia-Amirhosseini, PhD, Margaret Salfi, MS, Dieter Elhardt, PhD, Jeff Aycock, BS, Tsui Chern Cheah, BS, Alessandra Cesano, MD, David D. Hurd, MD

Blood (2005) 106 (11): 5294.

https://doi.org/10.1182/blood.V106.11.5294.5294

Published: 2005

Journal Articles

Should There Be an Upper Age Limit to Transplantation? A Pilot Questionnaire Survey.

Vallathvcherry Harish, MD, Yikong Keung, MD, Istvan Molnar, MD, James Lovato, MS, Julia Cruz, MD, David D. Hurd, MD

Blood (2004) 104 (11): 5322.

https://doi.org/10.1182/blood.V104.11.5322.5322

Published: 2004

Journal Articles

Phase 1 Study of Talabostat and Rituximab in Patients with Indolent Non-Hodgkin’s Lymphoma with Primary Resistance to or Progression Following Rituximab.

Ayad Al-Katib, MD, David D. Hurd, MD, Robert Raju, MD, Joe Stephenson, MD, Francis Giles, MD, Eric Haltom, Margaret J. Uprichard, PharmD

Blood (2004) 104 (11): 1403.

https://doi.org/10.1182/blood.V104.11.1403.1403

Published: 2004

NARROW

Low Pre-Transplant Vitamin D Levels Predict an Inferior Survival in Patients with Multiple Myeloma Undergoing an Autologous Stem Cell Transplant

Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance) 50403

The Mitochondrial Metabolism Inhibitor Cpi-613 in Combination with High Dose Ara-C (HDAC) and Mitoxantrone Is Highly Active in Poor Risk Relapsed or Refractory Acute Myeloid Leukemia (AML)

The Mitochondrial Metabolism Inhibitor Cpi-613 Is Highly Active in Combination with High Dose Ara-C (HiDAC) and Mitoxantrone in a Phase I Study for Relapsed or Refractory Acute Myeloid Leukemia (AML)

A Phase I Study Of The Safety, Efficacy and Pharmacokinetics Of The First In Class Pyruvate Dehydrogenase Complex Inhibitor Cpi-613 In Patients With Advanced Hematologic Malignancies

A Phase 2 Multicenter Study of Continuous Dose Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma

Phase III Intergroup Study of Lenalidomide (CC-5013) Versus Placebo Maintenance Therapy Following Single Autologous Stem Cell Transplant for Multiple Myeloma (CALGB 100104): Initial Report of Patient Accrual and Adverse Events.

A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma.

Vorinostat in Combination with Pegylated Liposomal Doxorubicin and Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase I Study.

A Phase II Multicenter Study of Lenalidomide in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL): Preliminary Results

A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) in Patients with Myelodysplastic Syndrome (MDS): Cancer and Leukemia Group B Study 10105.

A Phase I Open Label Dose Escalation Study To Evaluate MEDI-507 in Patients with CD2-Positive T-Cell Lymphoma/Leukemia.

Feasibility of Administering Oblimersen (G3139; Genasense) with Imatinib Mesylate in Patients with Imatinib Resistant Chronic Myeloid Leukemia (CML) - Cancer and Leukemia Group B Study 10107.

Pharmacokinetics (PK) of 2 Dosing Regimens of Palifermin in Patients (Pts) with Hematologic Malignancies (HM) Undergoing High-Dose Chemoradiotherapy and Hematopoietic Stem Cell Transplantation (HSCT).

Should There Be an Upper Age Limit to Transplantation? A Pilot Questionnaire Survey.

Phase 1 Study of Talabostat and Rituximab in Patients with Indolent Non-Hodgkin’s Lymphoma with Primary Resistance to or Progression Following Rituximab.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only